A Pfizer joint venture in India that manufactures injectable chemotherapy drugs for U.S. cancer patients remains closed ...

Facing looming patent cliffs, AstraZeneca has launched a restructuring initiative aimed at generating $1.5 billion in annual ...

Even as AbbVie has demonstrated that Rinvoq and Skyrizi sales can more than make up for Humira's tumble over the patent cliff ...

Next-generation antibody-drug conjugates, bispecifics, radiopharmaceuticals, tyrosine kinase inhibitors ... Fierce provides a ...

Amid a push to win back investor confidence in its R&D trajectory, Sanofi still has significant commercial powder to burn ...

Roughly one year into launch, Lenz Therapeutics, the maker of Vizz eye drops fo | In a massive overhaul of its operating ...

As the commercial momentum behind Lilly’s tirzepatide franchise continues, analysts are increasingly turning their attention ...

For that indication, Rytelo is dosed at 7.1 mg/kg administered as an intravenous infusion every four weeks. Thrombocytopenia ...

Even as a wave of clinical trial wins bolsters its momentum, Merck & Co. is prioritizing ongoing pipeline and commercial ...

Several months after telegraphing a major antibody-drug conjugate manufacturing expansion in its native Switzerland, CDMO ...

Eli Lilly is consolidating its U.S. and international commercial divisions into a unified department, tapping current U.S.

Saved by the Bell” actor Mark-Paul Gosselaar is the new face (and name) of AstraZeneca’s biomarker testing push, “Meet Your ...